Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  1. Outputs

Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?

Academic Article
Publication Date:
2018
Short description:
Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all? / Migrant Health Working Group for the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in, Eurocoord; Castagna, Antonella. - In: HIV MEDICINE. - ISSN 1464-2662. - (2018). [10.1111/hiv.12536]
abstract:
Objectives: The aim of the study was to evaluate differences in immunovirological response to combination antiretroviral therapy (cART) in migrant and native men and women within a European collaboration of HIV cohorts Collaboration of Observational HIV Epidemiological Research in Europ (COHERE) in EuroCoord, 2004-2013. Methods: Migrants were defined as those with geographical origin (GO) different from the reporting country and were grouped as originating from Western Europe and Western Countries (WEWC), Eastern Europe (EE), North Africa and the Middle East (NAME), sub-Saharan Africa (SSA), Latin America (LA), Caribbean (CRB) and Asia/Oceania (ASIA/OCE). Native (NAT) individuals were defined as those originating from the reporting country. CD4 cell counts were modelled using piecewise linear mixed-effects models with two slopes, whereas models to estimate subdistribution hazard ratios (sHRs) were used for time to virological response (VR) (i.e. time from cART initiation to the first of two successive HIV RNA measurements < 400 HIV-1 RNA copies/ml). Results: Of 32 817 individuals, 25 799 (78.6%) were men. The percentage of migrants was higher in women (48.9%) than in men (21.2%) and migrants from SSA accounted for the largest migrant group (29.9% in men and 63.3% in women). Migrant men and women from SSA started at lower CD4 cell counts than NAT individuals, which remained lower over time. VR was â ¥ 85% at 12 months for all groups except CRB women (77.7%). Compared with NAT men and women, lower VR was experienced by NAME [sHR 0.91; 95% confidence interval (CI) 0.86-0.97] and SSA (sHR 0.88; 95% CI 0.82-0.95) men and CRB (sHR 0.77; 85% CI 0.67-0.89) women, respectively. Conclusions: Immunovirological response to cART in Western Europe varies by GO and sex of patients. ART benefits are not equal for all, underlining the point that efforts need to prioritize those most in need.
Iris type:
1.1 Articolo in rivista
Keywords:
Combination antiretroviral therapy; HIV; Immunovirological response; Migrants; Sex; Health Policy; Pharmacology (medical); Infectious Diseases
List of contributors:
Migrant Health Working Group for the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in, Eurocoord; Castagna, Antonella
Authors of the University:
CASTAGNA ANTONELLA
Handle:
https://iris.unisr.it/handle/20.500.11768/68526
Published in:
HIV MEDICINE
Journal
  • Overview

Overview

URL

http://www.wiley.com/bw/journal.asp?ref=1464-2662
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.5.1.0